Originally, we wanted to do exactly as the word suggests," Ulrik Spork, managing partner at Novo Growth Equity, told BioWorld International

What the organization has seen is that the fund has become an important window on innovation for Merck Serono," he told BioWorld International

At the start of May, Elan was just about completing its transition from being a neurology-focused biotechnology firm to becoming an acquirer of companies and assets, with almost $2 billion of cash on a debt-free balance sheet and a steady income from royalties on sales of the blockbuster multiple sclerosis drug Tysabri (natalizumab), which is now under the sole control of Biogen Idec Inc., of Weston, Mass. (See BioWorld International, May 1, 2013.) Shareholders gave the latest news a very

Mario Labéta, senior lecturer at the Institute of Infection and Immunity at Cardiff University in Wales, told BioWorld International: "We have designed a novel strategy to boost the immune system, which has the potential to develop into a new therapy

We realized we needed to take a different approach to try and capture these opportunities," she told BioWorld International

At the start of May, Elan was just about completing its transition from being a neurology-focused biotechnology firm to becoming an acquirer of companies and assets, with almost $2 billion of cash on a debt-free balance sheet and a steady income from royalties on sales of the blockbuster multiple sclerosis drug Tysabri (natalizumab), which is now under the sole control of Biogen Idec Inc., of Weston, Mass. (See BioWorld International, May 1, 2013.) Shareholders gave the latest news a very

The date indicated refers to the BioWorld Today issue in which the news item can be found. ** Denotes the date the item ran in BioWorld International

the deal was part of a $498M orphan disease deal in 2010 5/3/13 Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found. ** Denotes the date the item ran in BioWorld International

Oxford expects to receive between £2.5M and £4M from Novartis over the next 12 months 5/2/13 Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found. ** Denotes the date the item ran in BioWorld International

Total Value in 2013: $6,192M* Number of Deals in 2013: 97 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date APRIL Alchemia Ltd. (Brisbane, Australia) AstraZeneca AB (Sodertalje, Sweden; unit of AstraZeneca plc) $240 Deal for Alchemia's Diversity Scanning Array and Versatile Assembly on Stable Templates technologies to discover and develop small molecules for multiple targets in the oncology, respiratory, cardiovascular, metabolism, infection and neuroscience

The Advanced Therapy Access Program for experimental treatments with the company's oncolytic viruses was made possible through European Union (EU) regulation EC/1394/2007, designed to improve safe access by patients across the EU to gene therapy, somatic cell therapy and tissue-engineered products that were not yet commercially available. (See BioWorld International, Sept. 6, 2006, and Nov. 1, 2006.) Under the experimental program, 290 patients from 20 countries were treated with the company's

It was a good process with good interest from the investors – notwithstanding the financial climate," he told BioWorld International

In addition to some benefits in terms of the underlying disease, CT327 showed a highly significant impact on itch, which in psoriasis and other dermatological diseases is the symptom that is the least well-managed," he told BioWorld International

Bert de Boer, group leader in the department of structural biology at Vrije Universiteit in the Netherlands, told BioWorld International: "Treatments for breast cancer are not as effective as we would like them to be, or the tumor may develop resistance to them

Its bookable profit will be almost €60 million (US$77.9 million), its chief financial officer and head of investor relations, Chris Tanner, told BioWorld International, as the company originally booked the shares at an average price of €1.77 per share

This is not a pure royalty model," an Elan spokesman told BioWorld International

Initially, Inviragen was looking for a partner that was capable of conducting later-stage development of its vaccine candidates," Dan Stinchcomb, co-founder and CEO, told BioWorld International

It's been a fantastic success," he told BioWorld International

The extra funding will be used "to extend the runway, not to add more programs," she told BioWorld International